Skip to content

Obturator to pelvic nerve rerouting for neurogenic bladder secondary to radical surgery of rectal, uterus or sacrum bone tumors

Obturator to pelvic nerve rerouting for neurogenic bladder secondary to radical surgery of rectal, uterus or sacrum bone tumors

Status
Recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2100043618
Enrollment
Unknown
Registered
2021-02-23
Start date
2021-03-01
Completion date
Unknown
Last updated
2021-06-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Neurogenic bladder

Interventions

1:Nerve rerouting

Sponsors

C.G. Xiao Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
5 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1.Male and female patients age 5 and older with neurogenic bladder voiding dysfunction secondary to radical hysterectomy, radical surgrey of rectum or sacral spine tumors, and on a CIC program for bladder management for at least one year prior to screening; 2.Atonic bladder documented by urodynamic testing during screening; 3.Documented history and no recurrence of the tumor; 4.Stable neurogenic bladder dysfunction of at least 1 year or more; 5.Normal renal function (cr normal); 6.Catheterized volume must be at least 50% of total bladder capacity.

Exclusion criteria

Exclusion criteria: 1.History of bladder augmentation, or radiation; 2.Anatomic outlet obstruction or urethral strictures; 3.History of untreated vesico-ureteric reflux grade 4 or higher documented on screening video UDT; 4.Subjects with an artificial bladder sphincter; 5.Subjects who have had a sling procedure; 6.Subjects who have had the mitrofanoff procedure; 7.Bladder botox injections within last 12 months; 8.Unable to ambulate independently with or without AFOs; 9.Subject is pregnant; 10.Contraindications to general anesthesia or surgery; 11.Inability to complete follow up visits for 1 years; 12.Inability to complete (or have parent complete) self administered questionnaires; 13.Subject possesses any other characteristics that, per investigator's judgment, deems them unsuitable (eg increases risk, impairs data collection, etc) for the procedure/study.

Design outcomes

Primary

MeasureTime frame
Voluntary voiding;

Secondary

MeasureTime frame
Residual urine;

Countries

China

Contacts

Public ContactChuan-Guo Xiao

C.G. Xiao Hospital

cgxiao_hospital@163.com+86 13686865959

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026